{"entity":{"id":"nct06703398","kind":"trial","name":"A Study of GC101 TIL in Advanced Melanoma","aka":[],"tldr":"A phase 2 trial of GC101 TIL, Dacarbazine, Temozolomide in melanoma, run by Shanghai Juncell Therapeutics, now recruiting.","summary":"A Study of GC101 TIL in Advanced Melanoma is a phase 2 interventional study registered as NCT06703398 by Shanghai Juncell Therapeutics, with 98 participants planned, started 2024-12-20 and due to reach its primary completion in 2026-05-12. Interventions recorded: GC101 TIL, dacarbazine, temozolomide, paclitaxel ,platinum or cisplatin. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06703398","url":"https://clinicaltrials.gov/study/NCT06703398"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["gc101-til","dacarbazine","temozolomide","paclitaxel"],"companies":["shanghai-juncell-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06703398","phase":"2","setting":"A Multicenter, Randomized, Controlled,Open Label, Phase II Trial of Autologous Tumor Infiltrating Lymphocytes (GC101 TIL) in Subjects With Advanced Melanoma","sponsor":"Shanghai Juncell Therapeutics","enrolled":98,"outcomes":[]},"route":"/trials/nct06703398/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"dacarbazine","kind":"drug","name":"Dacarbazine","route":"/drugs/dacarbazine/"},{"id":"gc101-til","kind":"drug","name":"GC101 TIL","route":"/drugs/gc101-til/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}],"company":[{"id":"shanghai-juncell-therapeutics","kind":"company","name":"Shanghai Juncell Therapeutics","route":"/companies/shanghai-juncell-therapeutics/"}]}}